Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Common Equity (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Common Equity for 13 consecutive years, with $296.7 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 69.03% to $296.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $296.7 million through Dec 2025, up 69.03% year-over-year, with the annual reading at $296.7 million for FY2025, 69.03% up from the prior year.
  • Common Equity for Q4 2025 was $296.7 million at Theravance Biopharma, up from $232.7 million in the prior quarter.
  • The five-year high for Common Equity was $480.6 million in Q3 2022, with the low at -$373.2 million in Q1 2021.
  • Average Common Equity over 5 years is $83.8 million, with a median of $199.3 million recorded in 2024.
  • The sharpest move saw Common Equity plummeted 136.31% in 2021, then surged 248.51% in 2022.
  • Over 5 years, Common Equity stood at -$338.6 million in 2021, then surged by 230.49% to $441.8 million in 2022, then plummeted by 51.79% to $213.0 million in 2023, then decreased by 17.58% to $175.5 million in 2024, then surged by 69.03% to $296.7 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $296.7 million, $232.7 million, and $224.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.